Polyrizon Ltd. has initiated preclinical studies for intranasal delivery of benzodiazepines (BZDs) using its proprietary Trap and Target™ platform. The focus is on treating acute repetitive seizures (ARS) and status epilepticus, conditions affecting millions globally and for which current treatments often prove inadequate. These studies, conducted in partnership with Professor Fabio Sonvico of the University of Parma, will evaluate the platform’s drug delivery capabilities using a model molecule that simulates the behavior of intranasal benzodiazepines.
This research is crucial because it addresses a significant unmet medical need: rapid and effective treatment for acute seizures. Current therapies often have limitations, and intranasal delivery could revolutionize treatment by providing faster, more accessible, and patient-friendly administration, particularly in out-of-hospital settings where immediate intervention is critical. This improved accessibility empowers caregivers, first responders, and patients themselves to manage seizures effectively, potentially preventing serious complications.
The preclinical studies will assess essential parameters such as drug loading, release rate, nasal deposition, and stability. Utilizing a model molecule at this stage allows researchers to refine the delivery system and understand how it interacts with the nasal cavity before moving to actual BZDs in later trials. This careful, stepwise approach helps maximize the chances of clinical success.
This research represents a significant advancement in acute seizure management. If successful, Polyrizon’s intranasal BZD delivery platform could drastically improve the quality of life for individuals with epilepsy, offering a more user-friendly and efficient way to control seizures. The positive impact on the industry could be considerable, potentially driving innovation in drug delivery technologies and leading to improved outcomes for patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
